Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

investments of dan watson as of 7/18/2019

image122

Seeking Biotech Alpha June 2019 Insight

AbbVie Inc. (ABBV)

image125

 AbbVie Inc. (ABBV) CEO Rick Gonzalez on Acquisition of Allergan Conference Call (Transcript)

Jun. 25, 2019 3:28 PM ET|83 comments  | About: AbbVie Inc. (ABBV) 

About: AbbVie Inc. (ABBV)

Empagliflozin

image126

 U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Wed June 26, 2019 6:00 AM|PR Newswire|About: LLY

  • - FDA's Fast Track designation for empagliflozin underscores the urgent need for new potential treatment options for the 6.5 million people in the U.S. who have heart failure

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 26, 2019 /PRNewswire/


 https://www.prnewswire.com/news-releases/us-fda-grants-fast-track-designation-to-empagliflozin-for-the-treatment-of-chronic-heart-failure-300874752.html 

JARDIANCE is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and also to reduce the risk of cardiovascular death in adults with type 2 diabetes who have known cardiovascular disease.

Seeking Biotech Alpha June 2019 Insight

DUOBRII™ (halobetasol propionate and tazarotene)

image129

 Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

Tue June 25, 2019 7:00 AM|Canada Newswire|About: BHC

LAVAL, Quebec, June 25, 2019 /CNW/ -- Bausch Health Companies Inc. (BHC

Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC

Gilead Sciences, Inc. (GILD) and Carna Biosciences Inc. (JASDAQ: 4572)

image131

Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies

Mon June 24, 2019 7:00 PM|Business Wire|About: GILD

FOSTER CITY, Calif. & KOBE, Japan--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) and Carna Biosciences Inc. (JASDAQ: 4572)


 https://www.carnabio.com/english/ 

Gilead and Carna Biosciences Announce Research and Development Collaboration to Develop Novel Immuno-Oncology Therapies FOSTER CITY, Calif. & KOBE, Japan--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) and Carna Biosciences Inc. (JASDAQ: 4572)

BRAFTOVI + MEKTOVI + Cetuximab

image132

Array BioPharma to Present Interim Analysis Results from Phase 3 BEACON CRC Trial of BRAFTOVI + MEKTOVI + Cetuximab for the Treatment of BRAFV600E- Mutant Metastatic Colorectal Cancer at the ESMO 21st World Congress on Gastrointestinal Cancer

Tue June 25, 2019 8:00 AM|PR Newswire|About: ARRY

BOULDER, Colo., June 25, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY

BRAFTOVI and MEKTOVI are prescription medicines used together to treat people with a type of skin cancer called melanoma: that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal “BRAF” gene

VENCLEXTA® (venetoclax) in combination with rituximab

image133

 AbbVie Receives Positive Recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for the Combination VENCLEXTA® With Rituximab as a Treatment for Patients With Chronic Lymphocytic Leukemia

Tue June 25, 2019 9:00 AM|Canada Newswire|About: ABBV 


 

  • INESSS recommends the reimbursement of VENCLEXTA® (venetoclax) in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukemia (CLL).i
  • Adult patients with CLL taking VENCLEXTA in combination with rituximab can stop their therapy after a defined treatment period of 24 months on treatment.

MONTREAL, June 25, 2019 /CNW/ - AbbVie (ABBV)


 https://www.rituxan.com/ 

VENCLEXTA is a prescription medicine used: to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who: are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy.

Vascepa® (icosapent ethyl)

image134

Amarin Corporation plc. (AMRN) CEO John Thero Presents at 2019 BMO Prescription For Success Healthcare Conference (Transcript)

Jun. 25, 2019 3:27 PM ET  | About: Amarin Corporation plc (AMRN) 


 https://amarincorp.com/ 

VASCEPA is a prescription medicine used along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats) in adults.

Seeking Biotech Alpha June 2019 Insight

seltorexant (MIN-202)

image135


  June 24, 2019

Minerva Neurosciences Announces Achievement of Primary and Key Secondary Objectives in Phase 2b Clinical Trial of Seltorexant (MIN-202) in Insomnia


 Minerva Neurosciences,... (NERV) 


 William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376 

Seltorexant (MIN-202) For the treatment of Insomnia and Mood Disorders

ProstaGene™ Prognostic Test

image137

FDA Grants Face-to-Face Meeting to Discuss CytoDyn’s 510(k) Application for ProstaGene™ Prognostic Test

Mon June 24, 2019 6:00 AM|GlobeNewswire|About: CYDY

VANCOUVER, Washington, June 24, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (CYDY),


 https://www.cytodyn.com/media/press-releases/detail/341/fda-grants-face-to-face-meeting-to-discuss-cytodyns 

Leronlimab PRO 140 The ProstaGene™ Prognostic Test is intended for use in patients who have undergone a prostate biopsy and been found to have prostate cancer by the Gleason score.

Acthar® Gel (Repository Corticotropin Injection)

image138

Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)

Mon June 24, 2019 6:55 AM|PR Newswire|About: MNK

STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK) (NYSE: MNK)

H.P. Acthar® Gel (repository corticotropin injection) is used for: Treatment for flares or on a regular basis (maintenance) in people with systemic lupus erythematosus (lupus) Treatment of infantile spasms in infants and children under 2 years of age Treatment for adults with acute relapses or flares of multiple sclerosis (MS). Studies have shown H.P. Acthar Gel to be effective in speeding recovery from an MS relapse. However, there is no evidence that Acthar affects the ultimate outcome or natural history of the disease The reduction of proteinuria in people with nephrotic syndrome of the idiopathic type (unknown origin) without uremia (accumulation of urea in the blood due to malfunctioning kidneys) or that due to lupus erythematosus (lupus) Treatment for flares or on a regular basis (maintenance) in people with systemic dermatomyositis or polymyositis (DM-PM) Treatment for people with symptoms of sarcoidosis Adjunctive therapy for short-term administration (to tide patients over an acute episode or exacerbation) in: psoriatic arthritis (PsA); rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis Treatment of severe acute and chronic allergic and inflammatory conditions affecting different parts of the eye. This can include the front part of the eye such as the cornea and iris, or the back part of the eye such as the optic nerve and retina Acthar is injected beneath the skin or into the muscle.

venetoclax (VENCLEXTA® OR VENCLYXTO®)

image140

 AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the t(11;14) Genetic Abnormality

  • Mon June 24, 2019 8:45 AM|PR Newswire|About: ABBV
  • - The t(11;14) genetic biomarker is among the most common and routinely tested genetic abnormalities in patients with multiple myeloma[1]

PR Newswire

NORTH CHICAGO, Ill., June 24, 2019 /PRNewswire/ -- AbbVie (ABBV


 VENCLEXTA/VENCLYXTO is being developed by AbbVie and Roche. It is jointly commercialized by AbbVie and Genentech, a member of the Roche Group, in the U.S. and by AbbVie outside of the U.S. Together, the companies are committed to BCL-2 research and to studying venetoclax in clinical trials across several blood and other cancers.  


 https://www.prnewswire.com/news-releases/abbvie-announces-us-fda-lifts-partial-clinical-hold-on-phase-3-study-of-venetoclax-in-patients-with-multiple-myeloma-positive-for-the-t1114-genetic-abnormality-300873381.html 



VENCLEXTA is a prescription medicine used: to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly-diagnosed acute myeloid leukemia (AML) who: are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy.

Seeking Biotech Alpha June 2019 Insight

BOTOX® (onabotulinumtoxinA)

image141

FDA Approves BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper Limb Spasticity

Fri June 21, 2019 7:30 AM|PR Newswire|About: AGN

  • --Approval Marks 10th BOTOX® Therapeutic Indication in its 30th Anniversary Year--

PR Newswire

DUBLIN, June 21, 2019 /PRNewswire/ -- Allergan plc (AGN)


 https://www.prnewswire.com/news-releases/fda-approves-botox-onabotulinumtoxina-for-pediatric-patients-with-upper-limb-spasticity-300872470.html 

BOTOX® is a prescription medicine that is injected into muscles and used: to treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken to treat leakage of urine (incontinence) in adults 18 years and older with overactive bladder due to neurologic disease who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication to prevent headaches in adults with chronic migraine who have 15 or more days each month with headache lasting 4 or more hours each day in people 18 years or older to treat increased muscle stiffness in elbow, wrist, finger, thumb, ankle, and toe muscles in people 18 years and older with upper and lower limb spasticity to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older to treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years and older

TALZENNA® (talazoparib)

image142

European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

Fri June 21, 2019 10:45 AM|Business Wire|About: PFE

Only once-daily PARP inhibitor approved in Europe for hereditary breast cancer

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE


 https://www.businesswire.com/news/home/20190621005322/en/ 

TALZENNA®–A Once-Daily Oral Treatment TALZENNA is a prescription medicine used to treat adults with: a certain type of breast cancer (human epidermal growth factor receptor 2 [HER2]-negative), and an abnormal inherited BRCA gene, and whose cancer has spread to other parts of the body (locally advanced or metastatic).

VeriSeq™ NIPT Solution

image143

 Illumina Introduces Expanded Version of VeriSeq™ NIPT Solution, Offering More Comprehensive Detection of Rare Chromosomal Conditions

Next-generation Sequencing-based Solution Provides Accurate, Fast and Scalable End-to-end Genome-wide Noninvasive Prenatal Testing

SAN DIEGO--(BUSINESS WIRE)--Jun. 4, 2019-- Illumina, Inc. (NASDAQ: ILMN

VeriSeq NIPT Solution Reagents, instruments, and CE-IVD marked library prep and analysis/reporting software in an automated workflow for in-lab prenatal aneuploidy screening.

SYMDEKO® (tezacaftor/ivacaftor and ivacaftor)

image144

 FDA Approves SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of CF in Children Ages 6-11 Years with Certain Mutations in the CFTR Gene

Fri June 21, 2019 2:30 PM|Business Wire|About: VRTX

-SYMDEKO is now approved for patients 6 years of age and older with two copies of the F508del mutation or one copy of a responsive mutation-

-Vertex (VRTX)'s third medicine approved to treat the underlying cause of CF in eligible patients in this age range-

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)


 https://www.businesswire.com/news/home/20190621005443/en/ 

SYMDEKO is a prescription medicine used for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have two copies of the F508del mutation, or who have at least one mutation in the CF gene that is responsive to treatment with SYMDEKO.

LUTONIX® Drug-Coated Balloons (DCBs)

image145

 BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices

Thu June 20, 2019 5:45 PM|PR Newswire|About: BDX

FRANKLIN LAKES, N.J., June 20, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)


 https://www.prnewswire.com/news-releases/bd-statement-on-fda-circulatory-system-devices-panel-regarding-paclitaxel-coated-devices-300872436.html 

LUTONIX® 035 Drug Coated Balloon PTA Catheter

Vascepa® (icosapent ethyl)

image146

 Amarin’s John Thero Awarded NJ EY Entrepreneur of The Year® 2019 Award for Life Sciences

Fri June 21, 2019 1:39 PM|GlobeNewswire|About: AMRN

BEDMINSTER, N.J. and DUBLIN, Ireland, June 21, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation (AMRN) plc (NASDAQ:AMRN)


 https://amarincorp.com/products.html 

VASCEPA is a prescription medicine used along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats) in adults. It is not known if VASCEPA changes your risk of having inflammation of your pancreas (pancreatitis). It is not known if VASCEPA prevents you from having a heart attack or stroke.

Seeking Biotech Alpha June 2019 Insight

ULTOMIRIS® (ravulizumab-cwvz)

image147

U.S. FDA Accepts Supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS)

Thu June 20, 2019 8:15 AM|Business Wire|About: ALXN

- FDA sets target action date of October 19, 2019 -

BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (ALXN

ULTOMIRIS is the first and only long-acting medication approved by the FDA, dosed every 8 weeks after the loading dose, to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).

Zanubrutinib in Combination with GAZYVA® (Obinutuzumab)

image148

BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML)

Thu June 20, 2019 11:05 AM|GlobeNewswire|About: BGNE

CAMBRIDGE, Mass. and BEIJING, China, June 20, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)



 https://www.gazyva.com/ 

BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination with GAZYVA® (Obinutuzumab) in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Follicular Lymphoma at the 15th International Conference on Malignant Lymphoma (ICML) June 20, 2019 11:05 ET | Source: BeiGene, LTD. CAMBRIDGE, Mass. and BEIJING, China, June 20, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160)

IL-33 antibody REGN3500 (SAR440340)

image149

 Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma

Fri June 21, 2019 12:59 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, June 21, 2019 /PRNewswire/ -- 

REGN3500 monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo

Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi

Our robust pipeline of investigational product candidates strives to address many serious medical conditions including asthma, pain, cancer and infectious diseases.

Janssen Announces Collaboration with University of California

image150

 Janssen Announces Collaboration with University of California, Berkeley and University of California, San Francisco to Expand Data Science Research in Healthcare

Thu June 20, 2019 9:00 AM|Business Wire|About: JNJ

The program facilitated by Johnson & Johnson Innovation will recruit data scientists to research high impact, data-science projects in healthcare

SAN FRANCISCO--(BUSINESS WIRE)-- Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)   


 https://www.businesswire.com/news/home/20190620005351/en/ 

data science health innovation fellowship program,

QIAGEN Clinical Insight (QCI®)

image151

QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and Interpreted

Thu June 20, 2019 10:00 AM|Business Wire|About: QGEN

Industry-leading bioinformatics software delivers genomic insights for precision medicine

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)-- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA)


 https://www.businesswire.com/news/home/20190620005371/en/ 

The recent explosion in the use of next-generation sequencing in the study of human disease has led to an exponential rise in the number of publications on the subject. With the burden of manual curation dramatically increasing, extracting valuable and up-to-date variant information is now a daunting task. Transform how you find answers with QIAGEN Clinical Insight Transparent, evidence-sourced NGS variant calling, interpretation and reporting

Editas Medicine, Inc. (EDIT)

image152

Editas Medicine (EDIT) Investor Presentation - Slideshow

Jun. 20, 2019 12:07 PM ET|2 comments | About: Editas Medicine, Inc. (EDIT) 

What if we could repair broken genes? What if we could address the root cause of diseases caused by mutations in our DNA?

Seeking Biotech Alpha June 2019 Insight

ELEVATE UC 52

image153

 Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Mon June 17, 2019 8:30 AM|PR Newswire|About: ARNA

  • - ELEVATE UC clinical trial sites continue to initiate

PR Newswire

SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) (Nasdaq: ARNA)

ETRASIMOD

LINZESS® (linaclotide)

image154

 Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Tue June 18, 2019 4:05 PM|Business Wire|About: AGN, IRWD 

LINZESS® (linaclotide) is a prescription medication used in adults to treat irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation (CIC). "Idiopathic" means the cause of the constipation is unknown

KANJINTI™ (trastuzumab-anns)

image155

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

  • Thu June 13, 2019 7:13 PM|PR Newswire|About: AGN, AMGN
  • Third FDA Approval From Amgen's Biosimilars Portfolio

PR Newswire

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN)

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab) Approval Based on Totality of Evidence Demonstrating KANJINTI is Biosimilar to Herceptin Third FDA Approval From Amgen's Biosimilars Portfolio THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN

BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

image156

 BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

Tue June 18, 2019 7:00 AM|GlobeNewswire|About: BGNE

CAMBRIDGE, Mass. and BEIJING, China and STAMFORD, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

SpringWorks Therapeutics is advancing a pipeline of standalone and combination therapies with an initial focus on severe rare diseases and oncology. We are working with urgency on behalf of the underserved patients living with these devastating illnesses.

Gilead and Nurix

image157

 Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

Wed June 19, 2019 8:30 AM|GlobeNewswire|About: GILDGlobeNewswire

FOSTER CITY, Calif. and SAN FRANCISCO, June 19, 2019 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels.

Amgen And The Institute For Protein Design (IPD) At University Of Washington

image158

 Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

Wed June 19, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD)


 https://www.prnewswire.com/news-releases/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-strategic-research-partnership-300871544.html 

The goal of the Institute for Protein Design is to develop and apply methods for designing a whole new world of synthetic proteins to address these challenges.

Seeking Biotech Alpha June 2019 Insight

Resiniferatoxin (RTX)

image159

Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

Wed June 19, 2019 7:00 AM|GlobeNewswire|About: SRNE 

RTX (non-opioid control of terminal cancer pain with a single injection)

REGN1979 is an investigational bispecific monoclonal antibody

image160

 Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

Fri June 14, 2019 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ 

une 14, 2019 at 7:00 AM EDT Back REGENERON CD20XCD3 BISPECIFIC REGN1979 SHOWS POSITIVE RESULTS IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA, INCLUDING IN CAR-T FAILURES TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ --

guselkumab (Tremfya(R))

image161

 MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

Fri June 14, 2019 8:20 AM|Accesswire|About: JNJ, MOR, MPSYY

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 14, 2019 / MorphoSys AG (MPSYF) (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) 

TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light or UV light).

ULTRA® Multifocal

image162

 Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

Wed June 19, 2019 7:00 AM|PR Newswire|About: BHC

New Lens is the Most Advanced Soft Contact Lens Design in Bausch + Lomb History

Only Multifocal Toric Lens that Offers Eye Care Professionals a Convenient Same-Day Fit to Address Patients with Astigmatism and Presbyopia

BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (BHC)

PRESBYOPIC CONTACT LENSES

Taltz® (ixekizumab)

image164

Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Fri June 14, 2019 3:24 PM|Canada Newswire|About: LLY

TORONTO, June 14, 2019 /CNW/ - Eli Lilly and Company (LLY)

Taltz is a prescription medicine also known as ixekizumab. Taltz is an injectable medicine used to treat adults: With moderate to severe plaque psoriasis. It is for people who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy). With active psoriatic arthritis.

Seeking Biotech Alpha June 2019 Insight

vosoritide

image166

BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

Tue June 18, 2019 8:31 AM|PR Newswire|About: BMRNPR Newswire

SAN RAFAEL, Calif., June 18, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN)

Vosoritide (BMN 111) for Achondroplasia Vosoritide is designed for the treatment of achondroplasia, the most common form of dwarfism.

tislelizumab, an investigational anti-PD-1 antibody,

image168

BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)

Fri June 14, 2019 2:30 AM|GlobeNewswire|About: BGNEGlobeNewswire

CAMBRIDGE, Mass. and BEIJING, China, June 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

Tislelizumab

Seeking Biotech Alpha June 2019 Insight

ORENCIA® (abatacept)

image172

 New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

Thu June 13, 2019 4:30 PM|Business Wire|About: BMY 

ORENCIA® (abatacept) ORENCIA is used to reduce signs and symptoms of moderate to severe Rheumatoid Arthritis (RA) in adults 18 years and older. Taking ORENCIA may prevent further damage to your bones and joints, and may help your ability to perform daily activities. ORENCIA may help those who are not getting the results they need with other medicines for RA.

CALQUENCE® (acalabrutinib)

image173

CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory  

Chronic Lymphocytic Leukemia

Sat June 15, 2019 7:00 AM|Business Wire|About: AZN

An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

WILMINGTON, Del.--(BUSINESS WIRE)--

CALQUENCE is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.

ULTOMIRIS® (ravulizumab)

image175

 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tue June 18, 2019 6:30 AM|Business Wire|About: ALXN 

ULTOMIRIS is the first and only long-acting medication approved by the FDA, dosed every 8 weeks after the loading dose, to treat adults with paroxysmal nocturnal hemoglobinuria (PNH).

KEYTRUDA® (pembrolizumab)

image176

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

Tue June 18, 2019 6:45 AM|Business Wire|About: MRK

Marks First Approval for KEYTRUDA in SCLC

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. These problems may happen any time during treatment or even after your treatment has ended.

Seeking Biotech Alpha June 2019 Insight

INGREZZA® (valbenazine)

image177

 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders

Tue June 11, 2019 4:01 PM|PR Newswire|About: NBIX

- Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerated in More than 500 Patients with Parkinson's Disease and Motor Fluctuations

PR Newswire

SAN DIEGO, June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX)


 https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2019-world-congress-on-parkinsons-disease-and-related-disorders-300865804.html 

INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

Rituxan® (rituximab), in combination with glucocorticoids (GCC)

image178

FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders

Wed June 12, 2019 1:00 AM|Business Wire|About: RHHBY

  • There are currently no FDA approved treatments for children living with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
  • The PePRS study is the first global trial of Rituxan in pediatric patients with GPA or MPA
  • Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis
  • If approved, this would be the first pediatric indication for Rituxan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

Rituxan is a prescription medicine used to treat adults with: Non-Hodgkin’s Lymphoma (NHL): alone or with other chemotherapy medicines. Chronic Lymphocytic Leukemia (CLL): with the chemotherapy medicines fludarabine and cyclophosphamide. Rheumatoid arthritis (RA): with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA in adults, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well enough. Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA): with glucocorticoids. Pemphigus Vulgaris (PV): to treat moderate to severe PV.

Zanubrutinib

image179

BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)

Wed June 12, 2019 4:00 AM|GlobeNewswire|About: BGNEGlobeNewswire

CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

Zanubrutinib (BGB-3111) — an investigational small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies.

ALKS 4230 in treating patients with renal cell carcinoma or melanoma

image181

 

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

Wed June 12, 2019 7:00 AM|PR Newswire|About: ALKS 


 PR Newswire

DUBLIN, June 12, 2019 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS) 


 https://www.prnewswire.com/news-releases/alkermes-advances-alks-4230-into-monotherapy-expansion-phase-of-artistry-1-in-patients-with-renal-cell-carcinoma-or-melanoma-300866051.html 


 http://www.alkermes.com/ 

A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors

oral semaglutide

image182

 Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

SAN FRANCISCO, June 11, 2019 /PRNewswire/

Ozempic® (semaglutide) injection 0.5 mg or 1 mg is an injectable prescription medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar.

Seeking Biotech Alpha June 2019 Insight

Array BioPharma (ARRY)

image183

 Array BioPharma (ARRY) Investor Presentation - Slideshow

Jun. 11, 2019 3:49 PM ET | About: Array BioPharma Inc. (ARRY) 

OUR PIPELINE

SKYRIZI™ (risankizumab)

image184

 June 11, 2019

New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance


 NORTH CHICAGO, Ill., June 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), 

SKYRIZITM (risankizumab-rzaa) is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).

INVOKANA® (canagliflozin)

image185

 INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis 

 SAN FRANCISCO, June 11, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson 

NVOKANA® is a prescription medicine used: along with diet and exercise to lower blood sugar (glucose) in adults with type 2 diabetes to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes who have known heart disease

PD-L1 IHC 22C3 pharmDx assay

image186

 

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

Tue June 11, 2019 7:56 AM|Business Wire|About: A

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab)

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A


 https://www.businesswire.com/news/home/20190611005542/en/ 

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC) PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab) June 11, 2019 07:56 AM Eastern Daylight Time SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A)

Bravos™ afterloader system for High Dose Rate (HDR) brachytherapy treatments

image187

Varian to Demonstrate New Bravos Afterloader System at ABS 2019

Tue June 11, 2019 8:15 AM|PR Newswire|About: VAR

PALO ALTO, Calif., June 11, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR

Varian to Demonstrate New Bravos Afterloader System at ABS 2019 June 11, 2019 PALO ALTO, Calif., June 11, 2019 /PRNewswire/ -- Varian (NYSE: VAR

Seeking Biotech Alpha June 2019 Insight

MAVYRET™ (glecaprevir and pibrentasvir)

image189

AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

Mon June 10, 2019 8:00 AM|Canada Newswire|About: ABBV

  • MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1
  • MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease (CKD).

MONTREAL, June 10, 2019 /CNW/ - AbbVie (ABBV)


 http://www.abbvie.ca/ 

MAVYRET™ (glecaprevir and pibrentasvir) tablets are a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.

KEYTRUDA® (pembrolizumab)

FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)

Tue June 11, 2019 6:45 AM|Business Wire|About: MRK

KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ≥1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)


 https://www.businesswire.com/news/home/20190611005275/en/ 

KEYTRUDA is a medicine that may treat certain cancers by working with your immune system. KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ≥1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression

Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab)

image191

FDA Grants Genentech’s Polivy Accelerated Approval for People with Previously Treated Aggressive Lymphoma

Mon June 10, 2019 12:36 PM|Business Wire|About: RHHBY

– New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen –

– First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells –

– Ninth indication with Breakthrough Therapy Designation in Genentech’s hematology portfolio to receive FDA approval –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)


 https://www.businesswire.com/news/home/20190610005588/en/ 

POLIVY is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have had at least 2 prior therapies.

XERAVA™ (eravacycline)

image192

Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting

Mon June 10, 2019 7:00 AM|Business Wire|About: TTPH

-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients-

-Data Underscore XERAVA’s Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections-

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH) (NASDAQ:TTPH)


 https://www.businesswire.com/news/home/20190610005030/en/ 

XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.

Vicinium®

image193

 Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®

Mon June 10, 2019 7:00 AM|Business Wire|About: SESN

FDA Recommends Accelerated Approval Pathway

FDA Indicated No Additional Clinical Trials Necessary for BLA Submission

Company Expects to Initiate Submission of the BLA in 4Q 2019 Under Rolling Review

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sesen Bio (SESN) (Nasdaq:SESN)


 https://www.businesswire.com/news/home/20190610005190/en/ 

Vicinium is being evaluated in the Phase 3 VISTA trial for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) who have been previously treated with bacillus Calmette-Guérin (BCG), which is the current standard of care for NMIBC.

Seeking Biotech Alpha June 2019 Insight

Tradjenta® (linagliptin)

image195

 

Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®

Mon June 10, 2019 9:30 PM|PR Newswire|About: LL 


 

  • Adults with diabetes treated with Tradjenta experienced fewer events of hypoglycemia and a modest weight reduction compared with glimepiride
  • - Detailed results from CAROLINA were presented at the American Diabetes Association's 79th Scientific Sessions

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 10, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY


 https://www.tradjenta.com/ 


 https://www.prnewswire.com/news-releases/detailed-findings-from-carolina-outcome-trial-support-long-term-cardiovascular-safety-profile-of-tradjenta-300864614.html 

TRADJENTA is a prescription medicine that is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

Taltz® (ixekizumab)

image196

 

Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Tue June 11, 2019 3:00 AM|PR Newswire|About: LLY

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY


 https://www.taltz.com/ 

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Gazyva (Obinutuzumab)

image197

Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study

Tue June 11, 2019 1:00 AM|Business Wire|About: RHHBY

  • NOBILITY showed that Gazyva helped more patients achieve a complete renal response when added to standard of care
  • The Phase II study met both primary and key secondary endpoints
  • There are currently no FDA-approved therapies for lupus nephritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)


 https://www.businesswire.com/news/home/20190610005836/en/ 

GAZYVA® (obinutuzumab) is a prescription medicine used in combination with chemotherapy, followed by GAZYVA alone in those who responded, to treat stage II bulky, III or IV follicular lymphoma (FL) in adults who have not had previous FL treatment. GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, bendamustine, followed by GAZYVA alone for follicular lymphoma (FL) in adults who did not respond to a rituximab-containing regimen, or whose FL returned after such treatment. GAZYVA® (obinutuzumab) is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous CLL treatment.

FARXIGA (dapagliflozin)

image199

FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

Mon June 10, 2019 8:00 AM|Business Wire|About: AZN

FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58

WILMINGTON, Del.--(BUSINESS WIRE)


 https://www.businesswire.com/news/home/20190610005198/en/ 

FARXIGA is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

BIOTECH-WARS™ & BIOTECH$TORM (DANWATSON BLOGS)

BIOTECH-WARS™

image283

 Jun. 8, 2019 5:21 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, CELG, LLY, MRK, PFE

Summary

politicos started the BIOTECH-WARS™ and they are continuing the war.

the BIOTECH-WAR$ led to the vilification of the biotech sector.

the Biotech industry severely miscalculated and underestimated the situation they find themselves in.

BIOTECH$TORM™ II

image284

 Jun. 5, 2019 4:18 PM ET|About: AbbVie Inc. (ABBV), AMGN, BMRN, CELG, JNJ, LLY, MRK, NVS, PFE, RHHBY

Summary

The perfect BIOTECH$TORM is not over, perhaps it is only in the early stages.

In NJ more taxes coming, more pain, more debt, unfunded liabilities, and in my view a rapid exit of many high-income people from my home state of New Jersey.

Nevertheless, meanwhile and more importantly Biotech Companies continue to make significant product and financial progress irrespective of the negative political environment that only seems to be getting worse.

 

BIOTECH$TORM™

image285

 Jun. 3, 2019 12:30 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, CELG, GILD, MRK, NVS, RHHBY, SGEN

Summary

The Perfect BIOTECH$TORM is occurring right now, June 2019.

Trade Wars, Legal Battles, Political Battles, all impact to create the Perfect BIOTECHSTORM.

Nevertheless Biotech companies continue to develop wonderful new products every day.

BIOTECH WAR$ 4

image286

 May 24, 2019 11:56 AM ET|About: Celgene Corporation (CELG), JNJ, LLY, MRK, NVS, Includes: ABBV, ARRY, MDT, PFE

Summary

the BIOTECH WAR$ have expanded to include a new and unexpected target, “wealthy people”.

the victorious party wants to remove all undesirable citizens/unlikely supporters from the state in which they live. Acrimony against biotech companies and now wealthy citizens is where we are at.

Biotech companies are an insufficient sector to the politico’s, and a more expansive “Bad Guy Group” is now needed – i.e., wealthy people, especially if you live in NJ

BIOTECH WAR$™ III

image287

 May 9, 2019 8:52 AM ET|About: Johnson & Johnson (JNJ), MRK

Summary

the BIOTECH WAR$ may represent a deeper battle going on between the “Socialist” political movement and our current “Capitalistic” economy.

Achieving political power supersedes common sense and support for the biotech business sector becomes non-existent as the sector is politically vilified.

Positive biotech product news seems to have little effect towards improving market valuations.

BIOTECH WAR$ II™

image288

 Apr. 30, 2019 5:44 PM ET|About: Amgen Inc. (AMGN), JNJ, MRK, Includes: BMY, CELG, NVO, NVS, PFE, RHHBY

Summary

The “Medicare for all” and the “drug pricing” messaging is working for all those who seek political gain.

Biotech, Medtech and the entire Healthcare sector are losing the battles, and the war as investors flee for less politically targeted sectors.

NJ residents see the "P/C", "Middle Class Only"/ Socialism wave coming.

I may need to stop being so publicly supportive of Biotech companies.

 

BIOTECH VORTEX™ & BIOTECH WARS (Danwatson blogs)

Biotech Vortex™

 Feb. 20, 2019 11:04 PM ET|Includes: AbbVie Inc. (ABBV), ABT, ALKS, AMGN, CELG, CERC, CLVS, JNJ, LLY, MDT, MRK, NVO, PFE

Summary

A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.

Biotech & Biotech Partnerships.

Biotech & Medtech Partnerships.

Biotech & Medtech & Medical Universities Partnerships.

Biotech & Health Systems Partnerships.

Biotech Vortex™ Feb. 20, 2019 11:04 PM ET|Includes: AbbVie Inc. (ABBV), ABT, ALKS, AMGN, CELG, CERC, CLVS, JNJ, LLY, MDT, MRK, NVO, PFE

Biotech, Biotech, Biotech,

  Mar. 6, 2019 8:12 AM ET|Includes: AbbVie Inc. (ABBV), AMGN, AZN, BMY, CELG, JNJ, LLY, MRK, PFE, SRPT

Summary

Sometimes biotech news is wonderful news.

Sometimes biotech news is the best and most upbeat news I read all day.

Sometimes with great effort and much time and money spent biotech news is remarkable news for many people seeking solutions to specific medical conditions and aliments.

The first 2 months of 2019 have been extremely strong for many of my biotech positions.


Biotech, Biotech, Biotech, Mar. 6, 2019 8:12 AM ET|Includes: AbbVie Inc. (ABBV), AMGN, AZN, BMY, CELG, JNJ, LLY, MRK, PFE, SRPT

IT’S BIOTECH OR NOTHIN’!™


 Feb. 1, 2019 9:27 PM ET|

6 comments |Includes: Abiomed, Inc. (ABMD), BIIB, ILMN, ISRG, MRK, RHHBY, SRPT, VA 


 Almost every piece of company news I was reading was positive and encouraging during the December 2018 time frame. 



IT’S BIOTECH OR NOTHIN’!™ Feb. 1, 2019 9:27 PM ET|6 comments |Includes: ABIOMED, Inc. (ABMD), BIIB, ILMN, ISRG, MRK, RHHBY, SRPT

BIOTECH WARS

 Feb. 12, 2019 4:16 PM ET|2 comments |About: AbbVie Inc. (ABBV), AZN, BMY, JNJ, MRK, PFE, SNY

Summary

Biotech companies are easy targets as they are on TV with their advertised products on a year-round basis and they are successful and profitable.

If an incumbent senator can successfully attack a successful and profitable biotech company, that is in his home state, then so can everyone else.

Should any politician target any biotech company in their home state, then most likely they will win votes and are more likely to win elections.

I think these hearings will eventually benefit biotech companies as insurance companies and PBM's and other "profiteers" in the healthcare pricing matrix are exposed.

As a biotech investor the upcoming/ongoing congressional hearings on drug pricing (2/26/2019) does have me feeling a bit on edge.   


BIOTECH WARS Feb. 12, 2019 4:16 PM ET|2 comments |About: AbbVie Inc. (ABBV), AZN, BMY, JNJ, MRK, PFE, SNY

BioTECH! ZONE

image289

  Apr. 2, 2019 8:20 PM ET|About: AstraZeneca PLC (AZN), BMY, CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY, SNY

Summary

“TINSTAAFL” = “There is no such thing as a free lunch”.

Princeton NJ/Central Jersey – is for me the best example of a successful BioTECH Zone.

Ireland's Life Sciences sector has grown from very humble beginnings in the 1960s to reach global significance. Collaborative clusters in Pharmaceutical, Biotechnology, Medical Devices and Diagnostics have been a key.

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China, that aims to nurture innovation.

Cambridge, Mass, is one of the best examples of a successful BioTECH Zone.

 

 


BioTECH! ZONE Apr. 2, 2019 8:20 PM ET|About: AstraZeneca PLC (AZN), BMY, CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY, SNY Summary “TINSTAAFL” = “There is no such thing as a free lunch”.

Bio-Tech & China, China, China

image290

 Mar. 14, 2018 1:14 PM ET|About: Amgen Inc. (AMGN), AZN, BGNE, CELG, NVS, Includes: ABMD, BMY, LLY, MDT, MRK, NVO

Summary

China Bio-Tech growth is accelerating now.

China needs better healthcare in every province.

China will welcome all bio-technology partnerships.

China is on the verge of major investment changes.

Bio-Tech & China, China, China Mar. 14, 2018 1:14 PM ET|About: Amgen Inc. (AMGN), AZN, BGNE, CELG, NVS, Includes: ABMD, BMY, LLY, MDT, MRK, NVO

Contact Us

send us a comment

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

seeking biotech alpha

Moorestown, New Jersey, United States

732-232-1334